Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: Predicting platinum resistance

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ferriss, J Stuart ^a   Kim, Youngchul ^b   Duska, Linda ^c   Birrer, Michael ^d   Levine, Douglas A ^e   Moskaluk, Christopher ^c   Theodorescu, Dan ^f   Lee, Jae K ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; ADJUVANT CHEMOTHERAPY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; TAXOIDS;

EID: 84863033309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030550     Document Type: Article

References (20)

1. ACS (2010) Cancer Facts & Figures American Cancer Society Atlanta.
2. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419-1425.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6.
4. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106.
5. Berger ML, Eck S, Ruberg SJ, (2010) Raising the bar of efficacy for drug approval requires an understanding of patient diversity. J Clin Oncol 28: e343-344.
6. Kern DH, Weisenthal LM, (1990) Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82: 582-588.
7. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, et al. (2006) Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16: 194-201.
8. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, (2007) A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18: 1093-1101.
9. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer. J Clin Oncol 25: 517-525.
10. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, et al. (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 104: 13086-13091.
11. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, et al. (2009) Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 69: 8302-8309.
12. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, et al. (2010) Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 16: 711-718.
13. Smith SC, Baras AS, Lee JK, Theodorescu D, (2010) The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 70: 1753-1758.
14. Peters D, Freund J, Ochs RL, (2005) Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 4: 1605-1616.
15. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
16. Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, et al. (2003) Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 4: R82.
17. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E, (2004) A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 10: 2922-2927.
18. Zhou XJ, Kao MC, Huang H, Wong A, Nunez-Iglesias J, et al. (2005) Functional annotation and network reconstruction through cross-platform integration of microarray data. Nat Biotechnol 23: 238-243.
19. Soukup M, Cho H, Lee JK, (2005) Robust classification modeling on microarray data using misclassification penalized posterior. Bioinformatics 21 (Suppl 1): i423-i430.
20. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525.